Table 2.
HIV latency reversal induced by immune checkpoint blockade or latency reversing agents in vitro.
| Immune checkpoint blockers | ||||
|---|---|---|---|---|
| Non-proliferating | Proliferating | |||
| No SEB | + SEB | No SEB | + SEB | |
| aPD-1 | 23.4 | 63.3 | 31.5 | 22.4 |
| Isot ctrl aPD-1 | 25.3 | 33.8 | 39.6 | 43.2 |
| aCTLA-4 | 38.6 | 66.3 | 39.3 | 53.2 |
| Isot ctrl aCTLA-4 | 27.0 | 52.3 | 47.8 | 37.1 |
| aPD-1+aCTLA-4 | 33.2 | 75.2 | 42.9 | 34.2 |
| Isot ctrl 2 ICB | 21.6 | 39.4 | 41.9 | 37.2 |
| aPD-1+aCTLA-4 +aTIM-3 | 40.5 | 65.3 | 49.6 | 40.7 |
| Isot ctrl 3 ICB | 22.9 | 30.2 | 31.7 | 36.8 |
| aPD-1+aCTLA-4 +aTIM-3+aTIGIT | 44.6 | 74.1 | 48.2 | 35.1 |
| Isot ctrl 4 ICB | 22.8 | 56.8 | 19.2 | 39.8 |
| Other LRAs | ||||
| Non-proliferating | Proliferating | |||
| DMSO | 7.0 | 2.7 | ||
| Romi 1 nM | 1.2 | 6.3 | ||
| Romi 0.1 nM | 5.1 | 7.2 | ||
| JQ1 1 μM | 2.7 | 2.0 | ||
| JQ1 0.1 μM | 5.2 | 7.8 | ||
| Bryo 10 nM | 50.9 | 42.6 | ||
| Bryo 1 nM | 64.8 | 47.4 | ||
| PMA+iono | 26.5 | 87.2 | ||
The percentage of maximal response induced following stimulation with anti-CD3 and anti-CD28 is shown. Increase in EGFP expression (latency reversal) is shown as the mean % of maximal activation with anti-CD3/28+IL-7+IL-2 following addition of IC blocking (ICB) antibodies or isotype control (isot ctrl), alone or in combination (top panels) or latency reversing agents (LRA; bottom panels). A grey box indicates a significant increase compared to isotype control (for immune checkpoint blockade or DMSO (for other LRAs), defined as p<0.05, using the frequency of EGFP+ cells shown in Figure S3. a = anti; Romi = romidepsin, bryo = bryostatin; PMA = phorbol 12-myristate 13-acetate; iono = ionomycin.